Physician

Thomas J Harris, M.D.

According to 2025 Medicare claims, Thomas Harris, M.D. (NPI: 1992789291) practices hematology/oncology in the Waco, TX market, with the plurality of this provider's patient population coming from Mc Lennan, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76712-2452. Harris is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Harris' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 489 traditional Medicare patients, billed 140,178 HCPCS/CPT codes, and received $2,944,337 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,421 prescription claims across 252 beneficiaries totaling $4,002,885 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 14 claims. Open Payments data shows 14 records totaling $9,594. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,393,634 to $2,944,337. Similarly, Part D prescription costs have risen steadily, from $611,519 to $4,002,885. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	422	102,310	$1,393,634
2016	555	142,518	$1,564,208
2017	622	141,159	$2,027,735
2018	584	135,519	$2,013,168
2019	564	197,458	$2,798,592
2020	559	148,868	$2,647,774
2021	496	123,669	$2,785,031
2022	497	140,883	$2,341,957
2023	501	145,982	$2,420,984
2024	489	140,178	$2,944,337

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	157	947	$611,519
2016	167	1,005	$972,998
2017	193	1,296	$1,638,818
2018	200	1,417	$1,869,308
2019	215	1,481	$2,551,510
2020	229	1,543	$3,228,616
2021	207	1,410	$3,076,872
2022	221	1,261	$3,181,867
2023	230	1,471	$3,070,432
2024	252	1,421	$4,002,885

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	106	$45,315
2016	N/R	32	$17,010
2017	N/R	12	$5,685
2018	N/R	N/R	N/R
2019	N/R	31	$4,494
2020	N/R	57	$4,154
2021	N/R	24	$1,488
2022	N/R	14	$895
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	255	642	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	81	96	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	226	464	$12
36415	Insertion of needle into vein for collection of blood sample	312	1,219	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	304	1,094	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	62	1,729	$1,133,576
Pomalyst	Pomalidomide	33	924	$746,827
Imbruvica	Ibrutinib	24	696	$402,406
Calquence	Acalabrutinib Maleate	25	705	$268,362
Brukinsa	Zanubrutinib	18	540	$241,121

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$120	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	7	$9,474	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas J. Harris, M.D.?

Tedicare shows public-source Medicare data for Thomas J. Harris, M.D. (NPI 1992789291), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas J. Harris, M.D. have ACO affiliation data?

Thomas J. Harris, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Thomas J. Harris, M.D.?

Thomas J. Harris, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Thomas J. Harris, M.D. have Open Payments data?

Thomas J. Harris, M.D. has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.